Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 814-820

  Akers, Lauren J ^a   Fang, Wendy ^b   Levy, Alejandro G ^c   Franklin, Anna R ^b   Huang, Peng ^b   Zweidler McKay, Patrick A ^b  

^a Cook Children's Hospital ^*  (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

ALL; AML; ATP; MTOR

Indexed keywords

3 BROMO 2 OXOPROPIONATE 1 PROPYL ESTER; ADENOSINE TRIPHOSPHATE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; PROPIONIC ACID DERIVATIVE; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MONOTHERAPY; PRIORITY JOURNAL;

ACUTE DISEASE; ADENOSINE TRIPHOSPHATE; ANTIMYCIN A; APOPTOSIS; CASPASE 3; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLYCOLYSIS; HL-60 CELLS; HUMANS; HYDROCARBONS, BROMINATED; IMMUNOBLOTTING; JURKAT CELLS; LEUKEMIA; PROPIONATES; SIROLIMUS; TIME FACTORS; U937 CELLS;

EID: 79955600630     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.028     Document Type: Article

References (34)

1. McNeil D.E., Cote T.R., Clegg L., Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 2002, 39(December (6)):554-557. [discussion 2-3].
2. Einsiedel H.G., von Stackelberg A., Hartmann R., Fengler R., Schrappe M., Janka-Schaub G., et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005, 23(November (31)):7942-7950.
3. Nguyen K., Devidas M., Cheng S.C., La M., Raetz E.A., Carroll W.L., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22(December (12)):2142-2150.
4. Shipley J.L., Butera J.N. Acute myelogenous leukemia. Exp Hematol 2009, 37(June (6)):649-658.
5. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Pediatr Clin North Am 2008, 55(February (1)):21-51. ix.
6. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65(January (2)):613-621.
7. Xu R.H., Pelicano H., Zhang H., Giles F.J., Keating M.J., Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005, 19(December (12)):2153-2158.
8. Pedersen P.L. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the " Warburg effect" , i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007, 39(June (3)):211-222.
9. Chen Z., Lu W., Garcia-Prieto C., Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007, 39(June (3)):267-274.
10. Hickey F.B., Cotter T.G. Identification of transcriptional targets associated with the expression of p210 Bcr-Abl. Eur J Haematol 2006, 76(May (5)):369-383.
11. Boag J.M., Beesley A.H., Firth M.J., Freitas J.R., Ford J., Hoffmann K., et al. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia 2006, 20(October (10)):1731-1737.
12. Herst P.M., Hesketh E.L., Ritchie D.S., Berridge M.V. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells. Leuk Res 2008, 32(February (2)):327-333.
13. Hulleman E., Kazemier K.M., Holleman A., VanderWeele D.J., Rudin C.M., Broekhuis M.J., et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009, 113(February (9)):2014-2021.
14. Pradelli L.A., Beneteau M., Chauvin C., Jacquin M.A., Marchetti S., Munoz-Pinedo C., et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2010, 29(March (11)):1641-1652.
15. Suganuma K., Miwa H., Imai N., Shikami M., Gotou M., Goto M., et al. Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leuk Lymphoma 2010, 51(November (11)):2112-2119.
16. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25(August (34)):4633-4646.
17. Kurtoglu M., Maher J.C., Lampidis T.J. Differential toxic mechanisms of 2-deoxy-d-glucose versus 2-fluorodeoxy-d-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 2007, 9(September (9)):1383-1390.
18. Geschwind J.F., Ko Y.H., Torbenson M.S., Magee C., Pedersen P.L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002, 62(July (14)):3909-3913.
19. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004, 324(November (1)):269-275.
20. Cao X., Fang L., Gibbs S., Huang Y., Dai Z., Wen P., et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007, 59(March (4)):495-505.
21. Tzung S.P., Kim K.M., Basanez G., Giedt C.D., Simon J., Zimmerberg J., et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001, 3(February (2)):183-191.
22. Park W.H., Han Y.W., Kim S.W., Kim S.H., Cho K.W., Kim S.Z. Antimycin A induces apoptosis in As4.1 juxtaglomerular cells. Cancer Lett 2007, 251(June (1)):68-77.
23. Loffler M. Towards a further understanding of the growth-inhibiting action of oxygen deficiency. Evaluation of the effect of antimycin on proliferating Ehrlich ascites tumour cells. Exp Cell Res 1985, 157(March (1)):195-206.
24. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294(November (5544)):1102-1105.
25. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100(February (4)):657-666.
26. Dancey J.E. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005, 14(March (3)):313-328.
27. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003, 100(December (25)):15113-15118.
28. Maniatis T., Fritsch E., Sambrook J. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, MA. 2nd ed.
29. Hervouet E., Cizkova A., Demont J., Vojtiskova A., Pecina P., Franssen-van Hal N.L., et al. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 2008, 29(August (8)):1528-1537.
30. Pan J.G., Mak T.W. Metabolic targeting as an anticancer strategy: dawn of a new era?. Sci STKE 2007, 2007(April (381)):pe14.
31. Pedersen P.L. The cancer cell's " power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr 2007, 39(February (1)):1-12.
32. Ihrlund L.S., Hernlund E., Khan O., Shoshan M.C. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008, 2(June (1)):94-101.
33. Hernlund E., Ihrlund L.S., Khan O., Ates Y.O., Linder S., Panaretakis T., et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123(July (2)):476-483.
34. Ledoux S., Yang R., Friedlander G., Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003, 63(November (21)):7284-7290.